Basit öğe kaydını göster

dc.contributor.authorDemircin, Guelay
dc.contributor.authorOener, Ayse
dc.contributor.authorErdogan, Oezlem
dc.contributor.authorDelibas, Ali
dc.contributor.authorBaysun, Sahika
dc.contributor.authorBuelbuel, Mehmet
dc.contributor.authorOksal, Ayseguel
dc.date.accessioned2020-06-21T15:18:10Z
dc.date.available2020-06-21T15:18:10Z
dc.date.issued2008
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.urihttps://doi.org/10.1080/08860220802132171
dc.identifier.urihttps://hdl.handle.net/20.500.12712/19602
dc.descriptionBEK, KENAN/0000-0002-1005-2379en_US
dc.descriptionWOS: 000258002700004en_US
dc.descriptionPubMed: 18661410en_US
dc.description.abstractIn this study, we evaluated the frequency, clinical presentation, treatment protocols, prognostic factors, and outcome in children with diffuse proliferative lupus nephritis (DPLN). Between June 1990 and December 2004, 46 patients were diagnosed to have systemic lupus erythematosus (SLE), and 26 of them (56.5%) were found to have DPLN. Renal manifestations were present in 25 patients, and the majority of them presented with severe renal findings, such as nephrotic syndrome and renal failure. All patients were given a quadruple therapy protocol including 6-12 monthly courses of methyl prednisolone pulse therapy combined with oral prednisolone, oral cyclophosphamide, azathioprine, and dipyridamole. Nineteen of these patients were regularly followed up with a mean follow-up period of 5.9 years. Complete remission was achieved in 15 of 19 patients, and chronic renal failure developed in four patients. Renal survival rate was calculated to be 78.9% at the end of 5, 10, and 14 years. Although nephrotic range proteinuria, hypoalbuminemia, renal failure, and activity index above 12/24 at presentation seemed to be associated with poor prognosis, no significant difference could be found. Hypertension and chronicity index greater than 6/12 were found to be bad prognostic predictors. We concluded that satisfactory results were achieved with our qadruple therapy protocol; thus, more aggressive and expensive therapies can be avoided and preserved for more serious and persistent diseases.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.isversionof10.1080/08860220802132171en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectdiffuse proliferative lupus nephritisen_US
dc.subjectchildhooden_US
dc.subjectclinical findingsen_US
dc.subjectquadruple therapyen_US
dc.subjectprognosisen_US
dc.titleLong-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritisen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume30en_US
dc.identifier.issue6en_US
dc.identifier.startpage603en_US
dc.identifier.endpage609en_US
dc.relation.journalRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster